Combination of polyclonal antibodies with anti-PD1 or anti-PDL1 antibodies for treating cancer

JP7578613B2Active Publication Date: 2024-11-06XENOTHERA
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2021564785
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-04-30
Filing Date
2020-04-28
Publication Date
2024-11-06
Estimated Expiration
2040-04-28

Smart Images

  • Figure 0007578613000001
    Figure 0007578613000001
  • Figure 0007578613000002
    Figure 0007578613000002
  • Figure 0007578613000003
    Figure 0007578613000003
Patent Text Reader

Abstract

The present invention relates to a combination of a non-human mammalian polyclonal antibody against cancer cells and at least one monoclonal antibody selected from the group consisting of anti-PD1 and anti-PDL1 monoclonal antibodies for use in preventing and / or treating cancer in a mammalian patient, and thus this combination is also contemplated.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] FIELD OF THEINVENTION The present invention relates to the field of immunology, in particular to combinations of polyclonal and monoclonal anti-PD1 and / or anti-PDL1 antibodies and their use in human medicine.

[0002] In particular, the present invention relates to the use of a combination of polyclonal non-human mammalian antibodies and monoclonal anti-PD1 and / or anti-PDL1 antibodies in the treatment of cancer.

[0003] 2. Description of Related Art Cancer is the second leading cause of death worldwide, responsible for an estimated 9.6 million deaths in 2018. Globally, approximately one in six deaths worldwide is due to cancer. Inaccessible or insufficiently active treatments are common in this field. Thus, there is a well-recognized need to develop new and improved therapeutic approaches to treat cancer.

[0004] Immunotherapy represents a real hope in the treatment of a great many cancers, especially those that cannot currently be cured effectively by conventional therapies. This treatment consists mainly of the administration of monoclonal antibodies against tumor cells or against activators or inhibitors of checkpoints of the immune response against the cancer.

[0005] Antibodies against tumors (passive immunotherapy) are two complementary approaches -by complement-dependent cytotoxicity (CDC) or antibody-dependent cellular cytotoxicity (ADCC) or antibody-dependent cellular phagocytosis (ADCP) -can act by triggering an adaptive immune response. Indeed, it has been demonstrated that opsonization of targets and local production of complement molecules (C3a, C5a) activates the costimulation of T lymphocytes and increases their survival (see Strainic et al., Immunity, 2008 Mar;28(3):425-35). Thus, passive administration of antitumor antibodies can, as a first step, cause the release of factors from complement that facilitate the T cell response in a second step.

[0006] However, 40% to 85% of patients are resistant to treatments based on the use of monoclonal antibodies. Evasion mechanisms include immune selection mechanisms, i.e. the ability of tumor cells to lose antigens recognized by the immune system, and immune collapse mechanisms (induction of specific tolerance). The emergence of poorly immunogenic tumor variants can be particularly detrimental in treatments based on the use of monoclonal antibodies (specific for unique epitopes).

[0007] Therefore, treatment based on the use of polyclonal antibodies targeting different epitopes on tumor cells may make it possible to minimize evasion mechanisms.

[0008] However, despite their potential effectiveness, polyclonal antibodies are rarely used in tumor treatment, especially due to the high toxicity risk in patients. This toxicity is mainly based on the fact that many cell surface antigens are expressed in many different cell types in the organism. This fact may result in major cross-reactivity with non-cancerous cells. This toxicity is also associated with the display of Neu5GC and alpha-1,3-galactose carbohydrates on animal immunoglobulins, where humans induce strong anti-Neu5GC and anti-alpha-1,3-galactose immune responses associated with allergies, serum sickness disease and the formation of immune complexes. Furthermore, these cross-reactivities were also associated with another problem of "diluting" the efficient antibodies in the organism, i.e., a significant amount of the administered polyclonal antibody population bound to a site different from the actual cancer target. This loss of effective antibodies in the targeted tumor required the administration of larger amounts of polyclonal antibodies to the patient, which of course led to an exacerbation of the associated toxic effects.

[0009] Thus, there remains a need in the art to provide effective and improved therapies for treating cancer that have reduced or no adverse effects.

[0010] The resistance of many tumors to treatments based on the use of monoclonal antibodies may also result from the presence of "non-inflammatory tumors" (Bonaventura et al, 2019; Front. Immunol.; 10; 168), i.e. tumors that, for various reasons, contain few infiltrating immune cells, especially few infiltrating T cells, and therefore do not provoke a strong response from the immune system and are therefore very difficult to treat with immunotherapy. Indeed, in this type of tumor, the response rate to therapeutic antibodies, for example therapeutic monoclonal antibodies targeting immune checkpoints commonly used to treat tumors, remains relatively low and therefore ineffective.

[0011] Thus, there remains a need in the art to provide effective treatments that allow for the treatment of non-inflammatory tumors.

[0012] There also remains a need in the art to provide means to convert non-inflammatory tumors into "hot tumors", i.e., tumors that contain sufficient or even higher levels of infiltrating T cells as explained above.

[0013] There remains a need in the art, in particular, to provide means to reduce the resistance of "non-inflammatory" tumors to monoclonal antibodies that target immune checkpoints by improving, i.e., enhancing, the ability of these tumors to be infiltrated by immune cells, particularly T cells and myeloid cells, especially T cells.

[0014] Summary of the Invention According to a first aspect, the present invention provides a method for preventing and / or treating cancer in a mammalian patient, comprising: - a non-human mammalian polyclonal antibody against cancer cells; - in combination with at least one monoclonal antibody selected from the group consisting of anti-PD1 and anti-PDL1 monoclonal antibodies.

[0015] The non-human mammalian polyclonal antibodies of the combination of the present invention are directed against cancer cells corresponding to or even belonging to the cancer to be prevented or treated in a mammalian patient.

[0016] The present inventors have demonstrated for the first time that the co-administration of polyclonal antibodies against cancer, particularly liver cancer, together with monoclonal anti-PDL1 antibodies in vivo provides unexpectedly high efficacy against target tumors, and in particular, a synergistic effect of these active substances on tumor treatment is observed.

[0017] Furthermore, after several weeks of treatment, surviving animals showed no evidence of visible disease by histopathological or toxicity assessment (no autoimmunity detected, i.e., animals showed no distress, weight loss, coloration, hair loss or diarrhea).

[0018] Thus, the inventors have succeeded in determining a new, effective, improved and non-toxic therapeutic approach for treating cancer.

[0019] In a particular embodiment, the polyclonal antibody of the combination of the invention comprises - a first antigenic determinant selected from the group consisting of (i) N-glycolneuraminic acid (Neu5Gc) and (ii) α-1,3-galactose; - different from the first antigenic determinant, it lacks a second antigenic determinant selected in the group consisting of (i) N-glycolneuraminic acid (Neu5Gc) and (ii) α-1,3-galactose.

[0020] In particular, the polyclonal antibody may lack two antigenic determinants: (i) N-glycolneuraminic acid (Neu5Gc) and (ii) α-1,3-galactose.

[0021] In a particular embodiment, the polyclonal antibody is an immunoglobulin G (IgG).

[0022] In a further embodiment, the monoclonal antibody of the combination of the invention is an anti-PDL1 antibody.

[0023] In another embodiment, the non-human mammal is selected from the group consisting of rodents, e.g., mice, rats, guinea pigs and hamsters; lagomorphs, e.g., rabbits; ferrets; felines, e.g., cats; canines, e.g., dogs; goats; sheep; bovines, e.g., cows; swines, e.g., pigs and hogs; camelids; horses and primates.

[0024] In particular, said non-human mammal may be selected from the group consisting of rodents, such as mice, rats, guinea pigs and hamsters, and lagomorphs, such as rabbits.

[0025] In particular, said non-human mammal may be selected from the group consisting of lagomorphs, goats, sheep, pigs, horses and bovines.

[0026] In certain embodiments, the mammalian patient is selected from the group consisting of rodents, e.g., mice, rats, guinea pigs and hamsters; lagomorphs, e.g., rabbits; ferrets; felines, e.g., cats; canines, e.g., dogs; goats; sheep; camels; bovines, e.g., cows; swines, e.g., pigs and hogs; alpacas; horses; primates and humans.

[0027] In particular, said mammalian subject may be selected from the group consisting of rodents, such as mice, rats, guinea pigs and hamsters.

[0028] In particular, said mammalian subject may be a human.

[0029] In certain embodiments, the mammalian subject can be selected from the group consisting of rodents, such as mice, rats, guinea pigs and hamsters, and humans.

[0030] In another embodiment, the cancer cells are selected from the group consisting of bladder cancer, breast cancer, colorectal cancer, kidney cancer, lung cancer, lymphoma, leukemia, myeloma, melanoma, oral or oropharyngeal cancer, pancreatic cancer, prostate cancer, thyroid cancer, uterine cancer, adenoid cystic cancer, adrenal tumors, amyloidosis, anal cancer, appendix cancer, bile duct cancer, bone cancer, brain cancer, central nervous system tumors, cervical cancer, esophageal cancer, eye cancer, eyelid cancer, gastrointestinal cancer, HIV / AIDS related cancer, lacrimal gland cancer, laryngeal or hypopharyngeal cancer, leukemia, liver cancer, meningioma, nasopharyngeal cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, parathyroid cancer, penile cancer, salivary gland cancer, sarcoma, non-melanoma skin cancer, small intestine cancer, stomach cancer, testicular cancer, thymoma and thymus cancer, vaginal cancer, and vulvar cancer.

[0031] In particular, the cancer cells are derived from liver cancer.

[0032] In a particular embodiment, the non-human mammalian polyclonal antibody and at least one monoclonal anti-PD1 or anti-PDL1 antibody are administered to a mammalian patient in the same composition or in separate compositions, preferably in separate compositions.

[0033] In another embodiment, the combination of the present invention comprises: - the non-human mammalian polyclonal antibody, and - further comprising at least one additional anti-cancer agent different from the monoclonal anti-PD1 or anti-PDL1 antibody.

[0034] In particular, the at least one additional anti-cancer agent can be a monoclonal antibody different from the monoclonal anti-PD1 or anti-PDL1 antibody.

[0035] In particular, the at least one additional anti-cancer agent can be a monoclonal antibody selected from the group consisting of anti-CD137, anti-CTLA4, anti-TIM-3, anti-B7-H3, anti-CD134, anti-CD154, anti-LAG-3, anti-CD227, anti-BTNA3, anti-CD39, anti-CD73, anti-CD115, anti-SIRP alpha, anti-SIRP gamma, anti-CD28, anti-NCR, anti-NKp46, anti-NKp30, anti-NKp44, anti-NKG2D, and anti-DNAM-1 monoclonal antibodies.

[0036] A further object of the present invention is to - a non-human mammalian polyclonal antibody against cancer cells; - in combination with at least one monoclonal antibody selected from the group consisting of anti-PD1 and anti-PDL1 monoclonal antibodies. [Brief description of the drawings]

[0037] [Figure 1] Figure 1 represents a graph showing the antiserum titers measured by ELISA. Serum was obtained from rabbits immunized with mouse tumor cells from the Hepa1.6 cell line (hepatocellular carcinoma), serially diluted and reacted with purified Hepa1.6 cells. Serum was collected from rabbits before immunization (rabbit-J0), 7 days after the first subcutaneous injection (rabbit-I1+7) and 7 days after the second subcutaneous injection (rabbit-I2+7). Vertical axis: optical density (DO 450 nm), horizontal axis: serial dilutions of collected serum. From left to right: 1:20; 1:60; 1:180; 1:540; 1:1620; 1:4860; 1:14580; 1:43740. [Diagram 2]Figure 2 represents the clinical scores measured in 8-week-old C57 / BL6J immune-competent mice for 30 days from the last injection of 2.5.106 Hepa1.6 cells into the portal artery. The different treatments were administered 4 days (D4) after the injection of Hepa1.6 cells. A clinical score of 1 corresponds to animals with bristly hairs and a slightly swollen abdomen. A clinical score of 2 corresponds to animals with a swollen abdomen and facial edema. A clinical score of 3 corresponds to animals with a swollen abdomen and exophthalmos. A clinical score of 4 corresponds to animals with a highly swollen abdomen (diameter > 9 cm), emaciation, hunched back, and isolation (leading to the euthanasia of the animals). Four treatment groups were formed. The first group (group 1; n=7; control) received a control isotype (3G8: irrelevant monoclonal antibody (mAb)-isotype IgG1) (8 mg / kg twice a week for 28 days) plus rabbit pre-immune polyclonal antibody (20 mg / kg twice a week for 28 days). The second group (group 2; n=8; comparison) received a control isotype (3G8: irrelevant monoclonal antibody (mAb)-isotype IgG1; 8 mg / kg twice a week for 28 days) plus polyclonal anti-Hepa1.6 cell antibody isolated from serum of immunized rabbits (20 mg / kg twice a week for 28 days). The third group (group 3; n=8) received monoclonal anti-PDL-1 antibody (8 mg / kg twice a week for 28 days) plus polyclonal anti-Hepa1.6 cell antibody isolated from serum of immunized rabbits (20 mg / kg twice a week for 28 days). The fourth group (group 4; n=7; comparison) received monoclonal anti-PDL-1 antibody (8 mg / kg twice a week for 28 days) plus pre-immune rabbit polyclonal antibody (20 mg / kg twice a week for 28 days). The obtained mean clinical values ​​are shown in the graph. Vertical axis: clinical score, horizontal axis: number of days. [Diagram 3] Figure 3 shows the survival rate of 8-week-old C57 / BL6J immune-competent mice for 50 days from the first day of treatment, which was performed 4 days after injection of 2.5.106 Hepa1.6 cells into the portal artery. Groups 1, 2, 3, and 4 shown are the same groups as those defined in Figure 2. Vertical axis: survival rate, horizontal axis: days. [Figure 4]Figure 4 represents the immunohistological results obtained by revealing either CD3+ T cells (first line) or LY6G+ myeloid cells (second line) in tumor biopsies. The tumors were obtained by subcutaneous implantation of B16F10 melanoma cells in Balb / C mice. The two groups were related as follows: - Group 1 (control pAb; n=7) received rabbit preimmune polyclonal antibody (20 mg / kg twice a week for 28 days); - Group 2 (anti-B16 pAb; n=8) received IgG fraction of antitumor polyclonal antibody obtained from rabbits immunized with mouse B16F10 melanoma cells, injected twice a week (12.5 mg / kg twice a week) from day 4 (D4) to day 30 (D30).

[0038] Detailed Description of the Invention 1.Definition In order to provide a more complete understanding of the present invention, certain definitions are set forth below. Such definitions are intended to encompass all grammatical equivalents.

[0039] The term "antibody" is used herein in the broadest sense. An "antibody" refers to any polypeptide that contains at least a binding polypeptide domain derived from (i) the Fc region and (ii) the variable region of an immunoglobulin. Thus, an antibody includes, but is not limited to, full-length immunoglobulins, antibodies, antibody conjugates, and fragments of each. The terms "antibody" and "immunoglobulin" can be used interchangeably herein.

[0040] The term "antibody" encompasses the above mentioned polypeptides which may contain or lack an antigenic determinant selected in the group comprising (i) N-glycolneuraminic acid (Neu5Gc) and / or (ii) α-1,3-galactose, in particular which may contain or lack the two antigenic determinants (i) N-glycolneuraminic acid (Neu5Gc) and (ii) α-1,3-galactose.

[0041] As used herein, "polyclonal antibodies" refers to a mixture of antibodies that recognize different epitopes of a given antigen and / or cell. Polyclonal antibodies include those contained in or alternatively derived from body fluids, particularly serum or plasma, from mammalian organisms, particularly non-human mammalian organisms.

[0042] In human immunoglobulins, light chains are classified as kappa and lambda light chains, and heavy chains are classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively.

[0043] As used herein, "IgG" refers to a polypeptide belonging to the antibody class substantially encoded by the recognized immunoglobulin gamma genes. In humans, IgG includes the subclasses or isotypes IgG1, IgG2, IgG3, and IgG4. In mice, IgG includes IgG1, IgG2a, IgG2b, IgG3. Full-length IgG consists of two identical pairs of immunoglobulin chains, each pair having one light chain and one heavy chain, each light chain containing immunoglobulin domains VL and CL, and each heavy chain containing immunoglobulin domains VH, Cγ1 (also called CH1), Cγ2 (also called CH2), and Cγ3 (also called CH3).

[0044] A "physiologically acceptable medium" according to the present invention means a carrier or excipient that is physiologically acceptable to the mammalian patient being treated while retaining the therapeutic properties of the compound being administered. One exemplary pharma- ceutically acceptable medium is physiological saline. Other physiologically acceptable mediums in the context of the present invention are known to those skilled in the art.

[0045] As used herein, "antibody-dependent cell-mediated cytotoxicity" (or ADCC) refers to a mechanism of cell-mediated immunity in which effector cells of the immune system actively lyse target cells bound to a specific antibody. ADCC is mediated mostly by NK cells, but also by other immune cells, such as neutrophils and eosinophils. Typically, ADCC occurs by activation of NK cells. Activation of NK cells involves the binding of their Fc receptors to the Fc region of IgG bound to antigens present on the surface of target cells. Such interaction triggers the release of cytokines and cytotoxic granules by the NK cells. To assess the ability of an antibody to trigger ADCC, an assay such as that described in de Romeuf et al. Br J Haematol. 2008 Mar;140(6):635-43 can be performed.

[0046] As used herein, "antigenic determinant" (or epitope) as applied herein to non-human mammalian polyclonal antibodies means a structural component of an antigenic molecule, including antigenic proteins and antigenic carbohydrates, that is responsible for its specific interaction with an antibody molecule elicited by the same or a related antigen. By extension, the term "antigenic determinant" as applied herein to non-human mammalian polyclonal antibodies is also used herein collectively to antigenic molecules that contain multiple epitopes susceptible to recognition by an antibody molecule elicited by the same or a related antigen. By way of example, the antigenic molecule N-glycol neuraminic acid (Neu5Gc) may be referred to herein as an "antigenic determinant," although the antigenic molecule may contain more than one epitope recognized by an antibody elicited by Neu5Gc or a Neu5Gc-containing molecule.

[0047] In blood, "serum" is the plasma-derived component from which cells (white and red blood cells) and clotting factors have been removed. Serum contains all proteins not used in blood clotting (clotting) and all electrolytes, antibodies, antigens, hormones, and ultimately any exogenous substances (e.g., drugs and microorganisms).

[0048] The terms "malignant cell", "cancer cell" and "tumor cell" can be used interchangeably herein. As used herein, "tumor cell" refers to a cell that autonomously hyperproliferates in vivo. Examples of tumor cells include: (1) sarcoma, such as osteosarcoma and soft tissue sarcoma; (2) cancer, such as breast cancer, lung cancer, bladder cancer, thyroid cancer, prostate cancer, colon cancer, colorectal cancer, pancreatic cancer, gastric cancer, liver cancer, uterine cancer, cervical cancer and ovarian cancer; (3) lymphoma, such as Hodgkin's lymphoma and non-Hodgkin's lymphoma; (4) neuroblastoma; (5) melanoma; (6) myeloma; (7) Wilms' tumor; (8) leukemia, such as acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL); (9) glioma; and (10) retinoblastoma.

[0049] As used herein, the term "cancer" refers to the uncontrolled, abnormal proliferation of cells and includes within its scope all known diseases caused by the uncontrolled, abnormal proliferation of cells. Non-limiting examples of common cancers include bladder cancer, breast cancer, ovarian cancer, and gastric cancer, cervical cancer, colon cancer, endometrial cancer, head and neck cancer, lung cancer, melanoma, multiple myeloma, leukemia (e.g., myeloid, lymphocytic, myelocytic and lymphoblastic leukemia), non-Hodgkin's lymphoma, prostate cancer, rectal cancer, malignant melanoma, and especially pancreatic cancer.

[0050] In particular, the cancer cells of the present invention can be cells contained in a cancer selected from the group consisting of bladder cancer, breast cancer, colorectal cancer, kidney cancer, lung cancer, lymphoma, melanoma, oral or oropharyngeal cancer, pancreatic cancer, prostate cancer, thyroid cancer, uterine cancer, adenoid cystic cancer, adrenal tumor, amyloidosis, anal cancer, appendix cancer, bile duct cancer, bone cancer, brain cancer, central nervous system tumor, cervical cancer, esophageal cancer, eye cancer, eyelid cancer, gastrointestinal cancer, HIV / AIDS related cancer, lacrimal gland cancer, laryngeal or hypopharyngeal cancer, leukemia, liver cancer, meningioma, nasopharyngeal cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, parathyroid cancer, penile cancer, salivary gland cancer, sarcoma, non-melanoma skin cancer, small intestine cancer, stomach cancer, testicular cancer, thymoma and thymus cancer, vaginal cancer and vulvar cancer.

[0051] In a particular embodiment, the cancer or tumor of the present invention is a non-inflammatory tumor. "Non-inflammatory tumor" is a term commonly used to refer to "non-inflamed" tumors, i.e., tumors characterized by the lack of infiltration of T cells. These are tumors that are generally known to be difficult because an adaptive immune response is not mounted or maintained. They are the opposite of "hot tumors" or "inflamed tumors." Inflamed tumors are tumors that are infiltrated by T cells in sufficient amounts to induce an adaptive response against them.

[0052] In particular, the non-inflammatory tumor may be selected from the group consisting of bladder cancer, breast cancer, colorectal cancer, kidney cancer, lung cancer, lymphoma, melanoma, oral or oropharyngeal cancer, pancreatic cancer, prostate cancer, thyroid cancer, uterine cancer, adenoid cystic cancer, adrenal tumors, amyloidosis, anal cancer, appendix cancer, bile duct cancer, bone cancer, brain cancer, central nervous system tumors, cervical cancer, esophageal cancer, eye cancer, eyelid cancer, gastrointestinal cancer, HIV / AIDS related cancer, lacrimal gland cancer, laryngeal or hypopharyngeal cancer, leukemia, liver cancer, meningioma, nasopharyngeal cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, parathyroid cancer, penile cancer, salivary gland cancer, sarcoma, non-melanoma skin cancer, small intestine cancer, stomach cancer, testicular cancer, thymoma and thymus cancer, vaginal cancer and vulvar cancer.

[0053] 2. Combinations of the Invention With a view to meeting the above mentioned objectives, and in particular to providing a new treatment against cancer, the improved efficiency of which is not associated with any observable toxicity in the treated organism, the inventors have - a non-human mammalian polyclonal antibody against cancer cells; -We have come up with a combination with at least one monoclonal antibody selected from the group consisting of anti-PD1 and anti-PDL1 monoclonal antibodies.

[0054] The anti-PD1 monoclonal antibody of the present invention can be selected, for example, from the group consisting of Nivolumab, Pembrolizumab, and Cemiplimab.

[0055] The anti-PDL1 monoclonal antibody of the present invention can be selected from the group consisting of, for example, Atezolizumab, Avelumab, and Durvalumab.

[0056] In a preferred embodiment, the monoclonal antibody of the combination of the invention is an anti-PDL1 antibody.

[0057] The combination of the present invention further comprises a non-human mammalian polyclonal antibody against cancer cells.

[0058] Polyclonal antibodies are directed against the same cancer cell, i.e., they all target different epitopes derived from different or the same antigen present on the surface of the same cancer cell.

[0059] The polyclonal antibody of the present invention is a) immunizing a non-human mammal against a cancer cell of interest; and b) collecting the antibodies contained in the body fluid of said non-human mammal of step a).

[0060] The step of immunizing a non-human mammal against the cancer cells of interest comprises injecting said cells into the non-human mammal.

[0061] Protocols for obtaining good levels of immunization of non-human transgenic mammals against cells are described, inter alia, in EP 0335804.

[0062] Such protocols consist in particular of immunizing animals such as rabbits, horses or pigs, preferably pigs, with repeated administrations of cancer cells according to known methods.

[0063] For example, with or without adjuvant, the ratio was 4.10 each time. 4 ~10 9 Several doses of cells are administered intravenously or subcutaneously, spaced at least one week apart. Approximately one week after the final immunization, serum is collected from the immunized animal and isolated according to known methods.

[0064] The step of harvesting the antibodies may consist, for example, of removing a portion of the blood fluid of the immunized non-human mammal from which the antibodies of interest are to be harvested.

[0065] According to a particular embodiment, said body fluid may be selected in the group comprising plasma and serum.

[0066] Protocols for obtaining blood fluids, especially plasma or serum, are within the general knowledge of a person skilled in the art.

[0067] According to a preferred embodiment, as mentioned above, the method for obtaining a polyclonal antibody of the present invention may further comprise a step of purifying the polyclonal antibody from said body fluid.

[0068] Said purification step is advantageous in that it makes it possible to overcome significantly the undesirable side effects that may be linked to the presence in body fluids of various cellular contaminants, which may involve the formation of corresponding contaminating antibodies by the immunized non-human mammal.

[0069] The purification step is also advantageous in that it makes it possible to obtain polyclonal antibodies having a desired purity.

[0070] Said purification steps are within the general knowledge of the person skilled in the art, as are all possible adaptations of any conventional purification protocol.

[0071] Suitable methods for purifying these polyclonal antibodies of interest include methods for purifying antibodies by affinity supports coupled to the antigen, Protein G or Protein A, such as those commercialized by ProteoGenix, Cell Biolabs, Inc. or CliniSciences, or further disclosed in EP 1601697, JP 7155194 or US 6,870,034.

[0072] Also included is an affinity support for selectively immobilizing an antibody of interest from blood fluid.The affinity support comprises a solid support material having an immobilized aptamer that specifically binds to the antibody of interest from blood fluid.Such a method is disclosed, inter alia, in WO 2010 / 094901.

[0073] According to a particular embodiment, the polyclonal antibody of the invention lacks a first antigenic determinant selected in the group comprising: (i) N-glycolneuraminic acid (Neu5Gc) and (ii) α-1,3-galactose.

[0074] According to a particular embodiment, the polyclonal antibody may further lack a second antigenic determinant different from the first antigenic determinant, wherein said second antigenic determinant is selected in the group comprising: (i) N-glycolneuraminic acid (Neu5Gc) and (ii) α-1,3-galactose.

[0075] Thus, the polyclonal antibody may lack two antigenic determinants: (i) N-glycolneuraminic acid (Neu5Gc) and (ii) α-1,3-galactose.

[0076] Polyclonal antibodies lacking these antigenic determinants are believed to have reduced immunogenic properties in humans compared to polyclonal antibodies that contain them.

[0077] It is known in the art that Neu5Gc is immunogenic in humans (Noguchi A. et al., J. Biochem. Tokyo (1995), 117(1): 59-62). Furthermore, it is known that most patients who develop severe immune complexes (IC) after animal immunoglobulin infusion express elevated antibodies against the Neu5Gc epitope (Merrick JM et al., Int. Allergy Appl. Immunol., 1978, Vol. 57: 477-480; Aggarwal S.et al., Nat Biotechnol. 2008;26:1227-1233; Arnold JN et al., Annu Rev Immunol. 2007;25:21-50; Durocher Y et al., Curr Opin Biotechnol. 2009;20:700-707; Higgins E et al., Glycoconj. J. 2009).

[0078] It is also known in the art that the α1,3-galactose (α1,3Gal) epitope (Galα1,3Galβ1,4GlcNAc-R) is synthesized by the enzyme α1,3-galactosyltransferase (α1,3GT or GGTA1) and that α1,3-galactose is the major xenoantigen causing hyperacute rejection in pig-to-human xenotransplantation.

[0079] According to these embodiments, the polyclonal antibody of the invention comprises: a) providing a genetically modified non-human mammal lacking a first gene selected from the group consisting of (i) a gene encoding a functional cytidine-5'-monophosphate N-acetylneuraminic acid hydrolase (CMAH) and (ii) a gene encoding a functional α-(1,3)-galactosyltransferase; b) immunizing the genetically modified non-human mammal against human cells; and c) collecting the antibodies contained in the body fluid of said genetically modified non-human mammal of step b).

[0080] Preferably, the genetically modified non-human mammal is a CMAH and / or GGTA1 knockout non-human transgenic mammal (or a CMAH and / or GGTA1 KO non-human mammal), including a CMAH and GGTA1 double knockout non-human transgenic mammal.

[0081] As used herein, a "knockout non-human transgenic mammal" consists of a non-human transgenic mammal in which the function of one or more alleles of the gene under consideration has been altered, e.g., by homologous recombination or other insertion or deletion.

[0082] In a particular embodiment, the gene is disrupted. By "disrupted gene" is meant that a portion of the genetic code is altered such that the transcription and / or translation of that segment of the genetic code is affected, for example, by knock-out techniques or by inserting an additional gene for a desired protein or by inserting a regulatory sequence that modulates the transcription of an existing sequence, thereby rendering that segment of the code unreadable.

[0083] In some embodiments, all cells of the non-human transgenic mammal contain the disrupted gene.

[0084] In a particular embodiment, a knockout non-human transgenic mammal is a non-human transgenic mammal in which one or more alleles of the gene under consideration are rendered non-functional.

[0085] In some embodiments, both alleles of the gene under investigation are rendered non-functional. Such embodiments include what are commonly referred to as "gene knockout", "gene knockin" and any other modification of one or more native alleles of the native gene under investigation that renders such gene non-functional. Such non-human transgenic mammals can be useful as sources for producing polyclonal antibodies of the invention.

[0086] Methods for obtaining a genetically modified non-human mammal lacking a selected gene in the group comprising (i) a gene encoding a functional cytidine-5'-monophosphate N-acetylneuraminic acid hydrolase and / or (ii) a gene encoding a functional α-(1,3)-galactosyltransferase are within the general knowledge of a person skilled in the art.

[0087] Methods for obtaining CMAH knockout non-human transgenic mammals are described, inter alia, in WO 2006 / 133356, which discloses, inter alia, a method for producing an animal product lacking N-glycolneuraminic acid (Neu5Gc) for human use, which comprises the steps of providing a genetically modified non-human mammal lacking a functional cytidine-5'-monophosphate N-acetylneuraminic acid hydrolase (CMAH) gene and removing at least one animal product from the genetically modified non-human animal.

[0088] Methods for obtaining GAL knockout non-human transgenic mammals are within the general knowledge of those skilled in the art (Cooper DK et al., Genetically engineered pigs, Lancet 1993, 342: 682; Lai L et al., Science 2002, 295: 1089; Sachs DH et al., Current Opinion in Organ Transplantation, 2009, 14:148-153).

[0089] Methods for obtaining GAL knockout non-human transgenic mammals are described, inter alia, in US Pat. No. 7,547,816.

[0090] As is known in the art, antibodies against mammalian cells, particularly cancer mammalian cells, can be readily obtained by immunizing a non-human mammal by administering an immunogenic composition containing the cancer cells of interest.

[0091] Methods intended to identify or characterize these specific forms of polyclonal antibodies of the present invention that lack a first antigenic determinant selected in the group comprising (i) N-glycolneuraminic acid (Neu5Gc) and (ii) α-1,3-galactose are within the general knowledge of the person skilled in the art.

[0092] Methods that can be used by one of skill in the art to identify or characterize such specific polyclonal antibodies of the present invention include enzyme-linked immunosorbent assays (ELISAs) in which anti-Neu5Gc and / or anti-Gal antibodies are used as detection molecules.

[0093] An example of an anti-Neu5Gc antibody for assessing the absence of the Neu5Gc antigenic determinant is the Gc-Free Basic Kit commercialized by Sialix, Inc.

[0094] As an anti-Gal antibody to demonstrate the absence of α-1,3-galactose antigenic determinants, the protocol disclosed by Jianq-Qiang Wang et al. (J. Am. Chem. Soc., 1999, 121: 8181) or the one commercialized by Sigma-Aldrich under the name WH0051083M1 Sigma can be considered.

[0095] In particular, the combination of the present invention - the non-human mammalian polyclonal antibody, and - further comprising at least one additional anti-cancer agent different from the monoclonal anti-PD1 or anti-PDL1 antibody.

[0096] In particular, the at least one additional anti-cancer agent can be a monoclonal antibody different from the monoclonal anti-PD1 or anti-PDL1 antibody.

[0097] In particular, the at least one additional anti-cancer agent can be a monoclonal antibody selected from the group consisting of anti-CD137, anti-CTLA4, anti-TIM-3, anti-B7-H3, anti-CD134, anti-CD154, and anti-LAG-3, anti-CD227, anti-BTNA3, anti-CD39, anti-CD73, anti-CD115, anti-SIRP alpha, anti-SIRP gamma, anti-CD28, anti-NCR, anti-NKp46, anti-NKp30, anti-NKp44, anti-NKG2D, and anti-DNAM-1 monoclonal antibodies.

[0098] 3. Medical Uses of the Invention As mentioned above, the present invention relates according to one of its aspects to a method for preventing and / or treating cancer in a mammalian patient, comprising: - a non-human mammalian polyclonal antibody against cancer cells; - in combination with at least one monoclonal antibody selected from the group consisting of anti-PD1 and anti-PDL1 monoclonal antibodies.

[0099] These polyclonal and monoclonal antibodies are described throughout the specification.

[0100] As stated above, the non-human mammalian polyclonal antibodies of the combination of the invention are directed against cancer cells corresponding to or even belonging to the cancer to be prevented or treated in a mammalian patient.

[0101] To treat a patient having the above mentioned needs, a therapeutically effective dose of the combination of the present invention may be administered.

[0102] By "therapeutically effective dose" herein is meant a dose that produces the effect for which it is administered. The exact dose will depend on the purpose of the treatment and will be ascertainable by one skilled in the art using known techniques.

[0103] Dosages can range from 0.001 to 100 mg per kg body weight (mg / kg) or more, for example, 0.1, 1.0, 10 or 50 mg / kg body weight of a polyclonal antibody of the invention. In particular, dosages can range from 0.1 to 100 mg / kg, or more particularly, 1 to 10 mg / kg of a polyclonal antibody of the invention.

[0104] The dosage may also be in the range of 0.001 to 100 mg per kg body weight (mg / kg) or more, for example, 0.1, 1.0, 10 or 50 mg / kg body weight of the anti-PD1 and / or anti-PDL1 monoclonal antibody of the invention. In particular, the dosage may be in the range of 0.1 to 100 mg / kg, or more particularly, 1 to 10 mg / kg of the anti-PD1 and / or anti-PDL1 monoclonal antibody of the invention.

[0105] The dosage and frequency of administration can be adapted depending on the host response and the frequency of injection for better tolerance.

[0106] For purposes of illustration only, the frequency of administration of the combination of the present invention can be daily administration for 5 to 15 consecutive days.

[0107] As is known in the art, adjustments for proteolysis, systemic versus local delivery, as well as age, weight, general health, sex, diet, timing of administration, drug interactions, and severity of the condition may be necessary and are readily determined by routine trial and error by one of ordinary skill in the art.

[0108] Administration of the combinations of the present invention can be achieved in a variety of ways, including, but not limited to, oral, subcutaneous, intravenous, parenteral, intranasal, intracortical, intraocular, rectal, vaginal, transdermal, topical (e.g., gel), intraperitoneal, intramuscular, intrapulmonary, or intrathecal.

[0109] In certain embodiments, the combination of the present invention is in a form suitable for administration by intravenous or parenteral route.

[0110] As mentioned above, the present invention provides a method for preventing and / or treating cancer in a mammalian patient, comprising: - a non-human mammalian polyclonal antibody against cancer cells; - in combination with at least one monoclonal antibody selected from the group consisting of anti-PD1 and anti-PDL1 monoclonal antibodies.

[0111] The non-human mammalian polyclonal antibody against cancer cells and at least one monoclonal antibody selected from the group consisting of anti-PD1 and anti-PDL1 monoclonal antibodies can be combined in one and the same composition or can be used in the form of separate compositions that can be administered simultaneously or sequentially.

[0112] In certain embodiments, the non-human mammalian polyclonal antibody against cancer cells and at least one monoclonal antibody selected from the group consisting of anti-PD1 and anti-PDL1 monoclonal antibodies are administered in separate compositions.

[0113] When the non-human mammalian polyclonal antibody against cancer cells and at least one monoclonal antibody selected from the group consisting of anti-PD1 and anti-PDL1 monoclonal antibodies are administered in separate compositions, the compositions can be administered to a mammalian patient via the same route or different routes, simultaneously or separately.

[0114] By simultaneously, it is understood that the compositions can be administered at the same moment or within the same day or over several days.

[0115] By separately it is understood that the compositions may be administered at least several days apart, for example at least 2 days apart.

[0116] In some embodiments, the polyclonal antibody compositions and anti-PD1 and / or anti-PDL1 monoclonal antibody compositions of the invention are in liquid form.

[0117] In some embodiments, the polyclonal antibody compositions and anti-PD1 and / or anti-PDL1 monoclonal antibody compositions of the invention are in a solid form, including a lyophilized form.

[0118] These compositions can be formulated according to standard methods, for example, as described in Remington: The Science and Practice of Pharmacy (Lippincott Williams & Wilkins; Twenty first Edition, 2005).

[0119] The above-mentioned compositions contain physiologically / pharmaceutical acceptable vehicles / excipients. The terms "physiologically acceptable" and "pharmaceutical acceptable" are used interchangeably herein.

[0120] Pharmaceutically acceptable excipients or vehicles which may be used are in particular those described in the Handbook of Pharmaceuticals Excipients, American Pharmaceutical Association (Pharmaceutical Press; 6th revised edition, 2009).

[0121] The combinations of the present invention may be used in combination with additional anti-cancer agents other than those mentioned above, including, for example, small molecules, other biologics, radiation therapy, surgery, etc. said non-human mammalian polyclonal antibody, -Can be administered with other therapies or therapeutic agents different from the monoclonal anti-PD1 or anti-PDL1 antibody.

[0122] According to a particular embodiment, the combination of the invention may further comprise, as other therapeutic agents, at least one immunosuppressant, such as, for example, glucocorticoids, cytostatics (azathioprine, methotrexate), antibodies or drugs acting on immunophilins (cyclosporine, tacrolimus, rapamycin).

[0123] These other therapeutic agents can be administered to a mammalian patient in the same composition as the non-human mammalian polyclonal antibody against cancer cells or at least one monoclonal antibody selected from the group consisting of anti-PD1 and anti-PDL1 monoclonal antibodies, or in a separate composition.

[0124] In particular, these other therapeutic agents are administered in a composition separate from the non-human mammalian polyclonal antibody against cancer cells or at least one monoclonal antibody selected from the group consisting of anti-PD1 and anti-PDL1 monoclonal antibodies.

[0125] In a particular embodiment, the present invention provides a method for the manufacture of a medicament for preventing and / or treating cancer in a mammalian patient, comprising: - a non-human mammalian polyclonal antibody against cancer cells; - use in combination with at least one monoclonal antibody selected from the group consisting of anti-PD1 and anti-PDL1 monoclonal antibodies.

[0126] In another embodiment, the present invention provides a method for the prevention and / or treatment of cancer in a mammalian patient, comprising administering to said mammalian patient: - a non-human mammalian polyclonal antibody against cancer cells; - administering a combination of at least one monoclonal antibody selected from the group consisting of anti-PD1 and anti-PDL1 monoclonal antibodies.

[0127] The present invention also relates to a compound according to the invention for use as a pharmaceutical, - a non-human mammalian polyclonal antibody against cancer cells; - in combination with at least one monoclonal antibody selected from the group consisting of anti-PD1 and anti-PDL1 monoclonal antibodies.

[0128] The invention is further illustrated by the following examples.

[0129] Working Example Example 1: ELISA control of polyclonal antibodies obtained by immunizing rabbits with cancer cell lines Rabbits are immunized with cells derived from the mouse tumor cell line Hepa1.6 (hepatocellular carcinoma) to obtain the corresponding anti-tumor polyclonal antibodies.

[0130] The tumor cells are injected subcutaneously twice, two weeks apart.

[0131] Sera are actually collected from rabbits before immunization (rabbit-J0), 7 days after the first subcutaneous injection (rabbit-I1+7) and 7 days after the second subcutaneous injection (rabbit-I2+7) to test the ability of the antibodies to recognize the tumor cells used to immunize the rabbits.

[0132] In particular, the antibody response of the immunized rabbits is measured using a cell ELISA test based on the Hepa1.6 cells used to immunize the rabbits. The collected sera are serially diluted 1:20; 1:60; 1:180; 1:540; 1:1620; 1:4860; 1:14580; 1:43740 in PBS-0.05% bovine serum albumin and incubated for 2 hours at room temperature. After centrifugation and washing of the ELISA plate, taking care not to aspirate the cells, peroxidase-labeled goat anti-rabbit antibody (1 / 1000 dilution) is added, incubated for 1 hour, and washed again. Then, 50 microliters of TMB are added and incubated for 15 minutes in the dark. After adding 10 microliters of HCL, the optical density is read at 450 nm.

[0133] The results are shown in FIG.

[0134] comment Polyclonal antibodies obtained in the serum collected after the second injection are found to efficiently recognize the desired target tumor cells.

[0135] Example 2: In vivo use of harvested polyclonal antibodies in syngeneic and orthotopic mouse models The Hepa1.6 hepatocellular carcinoma mouse model described in Gauttier et al., Int J Cancer. 2014 Dec 15;135(12):2857-67 was used.

[0136] This model is both syngeneic and orthotopic in immune-competent C57 / BL6J mice.

[0137] 2.5.10 Resuspended in PBS 6 Hepa1.6 cells are injected into the portal vein of 8-week-old male mice, which, if left untreated, leads to hepatic hypertension and the death of the animals after 12-15 days.

[0138] The different treatments were administered 4 days later (D4).

[0139] The first group (Group 1; n=7; control) received a control isotype (3G8: irrelevant monoclonal antibody (mAb)-isotype IgG1) (8 mg / kg twice weekly for 28 days) plus rabbit pre-immune polyclonal antibody (20 mg / kg twice weekly for 28 days).

[0140] The second group (group 2; n=8; comparison) received a control isotype (3G8: irrelevant monoclonal antibody (mAb)-isotype IgG1; 8 mg / kg twice a week for 28 days) plus a polyclonal anti-Hepa1.6 cell antibody isolated from the serum of immunized rabbits (20 mg / kg twice a week for 28 days).

[0141] The third group (group 3; n=8) received monoclonal anti-PDL-1 antibody (8 mg / kg twice weekly for 28 days) plus polyclonal anti-Hepa1.6 cell antibody isolated from the serum of immunized rabbits (20 mg / kg twice weekly for 28 days).

[0142] The fourth group (group 4; n=7; comparison) received monoclonal anti-PDL-1 antibody (8 mg / kg twice weekly for 28 days) plus rabbit preimmune polyclonal antibody (20 mg / kg twice weekly for 28 days).

[0143] The polyclonal antibodies used correspond to IgG antibodies obtained according to Example 1 and purified from rabbit serum using methods well known to those skilled in the art, including affinity columns on protein A.

[0144] Following these treatments, the clinical scores of the different groups are observed over a period of 30 days after tumor cell injection.

[0145] The results obtained are presented in FIG.

[0146] Clinical scores from 0 to 4 are as follows:

[0147] A clinical score of 1 corresponds to animals with bristles and slightly swollen abdomen. A clinical score of 2 corresponds to animals with swollen abdomen and facial edema. A clinical score of 3 corresponds to animals with swollen abdomen and exophthalmos. A clinical score of 4 corresponds to animals with severely swollen abdomen (>9 cm diameter), emaciation, hunched back, and isolation (leading to the euthanasia of the animal).

[0148] comment As expected, in the control untreated Group 1, all mice died by 15 days after cell injection (represented in FIG. 3).

[0149] The results observed are similar for groups 2 and 4, which correspond to the administration of either the purified polyclonal antibody obtained as mentioned above or the monoclonal anti-PDL1 antibody. These two separate treatments reduce the clinical score to about 3 after 25 days.

[0150] In contrast, a synergistic effect is observed in animals of group 3 treated with a combination of the polyclonal antibody of the invention and an anti-PDL1 monoclonal antibody, since they maintain a clinical score of 0-1 until day 30 (end of the experiment).

[0151] Surprisingly, careful observation of the mice in group 3 over the next few days of the experiment failed to observe any toxicity, in particular any autoimmune signs (i.e., no distress, weight loss, pigmentation, hair loss or diarrhea in the animals).

[0152] Example 3: Polyclonal antibodies of the invention allow the conversion of non-inflammatory tumors into inflammatory tumors Rabbits are immunized with mouse B16F10 melanoma cells to obtain corresponding anti-tumor polyclonal antibodies.

[0153] The B16F10 melanoma cell line is known to be a good example of a "non-inflammatory" tumor, for example, because it is resistant to anti-PDL1 antibodies, where such antibodies have very limited effect on tumor regression (Chen et al., Cancer Immunol res. 2014; 3(2):149-60; Ueha et al., 2015; 3(6):631-40).

[0154] IgG fractions of these rabbit-derived polyclonal antibodies raised against B16F10 cells are injected twice weekly (12.5 mg / kg twice weekly) from day 4 (D4) to day 30 (D30) into Balb / C mice (group 2-n=8) subcutaneously implanted with B16F10 melanoma cells (D0).

[0155] A control group of animals (group 1-n=7) implanted subcutaneously with B16F10 melanoma cells also received rabbit pre-immune polyclonal antibody alone (20 mg / kg twice weekly for 28 days).

[0156] Tumor biopsies are taken and analyzed by immunohistology 30 days after injection of the cells (for group 2) or 18 days after said injection for group 1 (as all the animals in this group have died).

[0157] CD3+ T cells and LY6G+ bone marrow cells are revealed as shown in FIG.

[0158] A significantly higher infiltration by T cells and myeloid cells is observed in the tumors of animals that received the polyclonal antibodies of the invention directed against said tumors.

[0159] Therefore, it was found that the polyclonal antibody of the present invention induced the infiltration of CD3+ T cells and myeloid immune cells into the tumor bed.

[0160] Thus, it converts a known "non-inflammatory" tumor into an "inflammatory" tumor, thereby allowing anti-PD1 / anti-PDL1 to prevent tumor cells from inactivating T cells that are now in access to the tumor, thereby effectively fulfilling their role in enabling the immune system to work in full force against the tumor.

Claims

1. For use in preventing and / or treating cancer in a mammalian patient, - a non-human mammalian polyclonal antibody against cancer cells; with at least one monoclonal antibody selected from the group consisting of anti-PD1 and anti-PDL1 monoclonal antibodies, Combination medicines.

2. The polyclonal antibody - a first antigenic determinant selected from the group consisting of (i) N-glycolneuraminic acid (Neu5Gc) and (ii) α-1,3-galactose; - a second antigenic determinant which, different from the first antigenic determinant, is selected in the group consisting of (i) N-glycolneuraminic acid (Neu5Gc) and (ii) α-1,3-galactose.

3. The pharmaceutical combination for use according to claim 1 or 2, wherein the polyclonal antibody lacks the two antigenic determinants (i) N-glycolneuraminic acid (Neu5Gc) and (ii) α-1,3-galactose.

4. The pharmaceutical combination for use according to any one of claims 1 to 3, wherein the polyclonal antibody is immunoglobulin G (IgG).

5. The combination drug for use according to any one of claims 1 to 4, wherein the monoclonal antibody is an anti-PDL1 antibody.

6. The pharmaceutical combination for use according to any one of claims 1 to 5, wherein the non-human mammal is selected from the group consisting of rodents; lagomorphs; ferrets; felines; canines; goats; sheep; bovines; swine; camelids; horses and primates.

7. The pharmaceutical combination for use according to any one of claims 1 to 6, wherein said non-human mammal is selected from the group consisting of rodents and lagomorphs.

8. The pharmaceutical combination for use according to any one of claims 1 to 7, wherein the mammalian patient is selected from the group consisting of rodents; lagomorphs; ferrets; felines; canines; goats; sheep; camels; bovines; swine; alpacas; horses; primates and humans.

9. The pharmaceutical combination for use according to any one of claims 1 to 8, wherein the mammalian patient is a human.

10. 10. The pharmaceutical combination for use according to any one of claims 1 to 9, wherein the cancer cells are selected from the group consisting of bladder cancer, breast cancer, colorectal cancer, kidney cancer, lung cancer, lymphoma, leukemia, myeloma, melanoma, oral or oropharyngeal cancer, pancreatic cancer, prostate cancer, thyroid cancer, uterine cancer, adenoid cystic cancer, adrenal gland tumor, amyloidosis, anal cancer, appendix cancer, bile duct cancer, bone cancer, brain cancer, central nervous system tumor, cervical cancer, esophageal cancer, eye cancer, eyelid cancer, gastrointestinal cancer, HIV / AIDS related cancer, lacrimal gland cancer, laryngeal or hypopharyngeal cancer, leukemia, liver cancer, meningioma, nasopharyngeal cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, parathyroid cancer, penile cancer, salivary gland cancer, sarcoma, non-melanoma skin cancer, small intestine cancer, stomach cancer, testicular cancer, thymoma and thymus cancer, vaginal cancer and vulvar cancer.

11. The combination pharmaceutical for use according to any one of claims 1 to 10, wherein the cancer cells are derived from liver cancer.

12. The combination pharmaceutical for use according to any one of claims 1 to 11, wherein the cancer cells are derived from a cold tumor.

13. The pharmaceutical combination for use according to any one of claims 1 to 12, wherein said non-human mammalian polyclonal antibody and said at least one monoclonal anti-PD1 or anti-PDL1 antibody are administered to a mammalian patient in the same composition or in separate compositions.

14. The combination pharmaceutical for use according to any one of claims 1 to 13, further comprising at least one additional anti-cancer agent different from the non-human mammalian polyclonal antibody and the monoclonal anti-PD1 or anti-PDL1 antibody.

15. 15. The pharmaceutical combination for use according to claim 14, wherein the at least one additional anti-cancer agent is in particular selected from the group consisting of anti-CD137, anti-CTLA4, anti-TIM-3, anti-B7-H3, anti-CD134, anti-CD154, anti-LAG-3, anti-CD227, anti-BTNA3, anti-CD39, anti-CD73, anti-CD115, anti-SIRP alpha, anti-SIRP gamma, anti-CD28, anti-NCR, anti-NKp46, anti-NKp30, anti-NKp44, anti-NKG2D and anti-DNAM-1 monoclonal antibodies.

16. - a non-human mammalian polyclonal antibody against cancer cells; with at least one monoclonal antibody selected from the group consisting of anti-PD1 and anti-PDL1 monoclonal antibodies, Combination medicines.

Citation Information

Patent Citations

  • Composition with reduced immunogenicity

    WO2016059161A1